ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

ADVFN

Trade Now

EasyMarkets
Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P 500
4,604.37
(
0.41%
)
US Tech 100
15,664.00
(
-0.15%
)
Dow Jones
36,247.87
(
0.36%
)
Brent Oil
75.615
(
-0.49%
)
Bitcoin
42,394.20
(
-3.17%
)
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Amarin Corp PLC (AMRN)

  7. Amarin Corp PLC (AMRN) News

AMRN Amarin Corp PLC

0.8566
0.00 (0.0%)
Pre Market
Last Updated: 04:00:06
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Amarin Corp PLC AMRN NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
Upgrade Icon
0.00 0.0% 0.8566 04:00:06
Open Price Low Price High Price Close Price Prev Close
0.8566
more quote information »

Recent News

Date Time Source Heading
12/05/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/05/202307:30EDGAR2Form SC 13D/A - General statement of acquisition of..
11/12/202309:00GLOBENew REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)..
11/03/202316:30EDGAR2Form 8-K - Current report
11/01/202307:05EDGAR2Form 8-K - Current report
11/01/202307:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/01/202307:00GLOBEAmarin Reports Third Quarter 2023 Financial Results
10/31/202316:05EDGAR2Form 8-K - Current report
10/31/202312:00GLOBEAmarin Appoints Jonathan Provoost Executive Vice President,..
10/26/202308:00GLOBELatest Research Evaluating VASCEPA®/VAZKEPA® (icosapent..
10/19/202308:00GLOBE Amarin to Report Third Quarter 2023 Financial Results and..
9/12/202308:00GLOBEAmarin to Present at the 2023 Cantor Global Healthcare..
9/05/202316:15EDGAR2Form SC 13D/A - General statement of acquisition of..
8/16/202319:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/16/202300:15EDGAR2Form EFFECT - Notice of Effectiveness
8/09/202316:05GLOBEAmarin Provides Pricing & Reimbursement Updates for VAZKEPA..
8/08/202307:00GLOBEAmarin And Neopharm Announce Exclusive Commercialization..
8/07/202307:00GLOBEScottish Medicines Consortium Accepts VAZKEPA® (icosapent..
8/02/202317:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/02/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/02/202317:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/02/202308:39EDGAR2Form S-8 - Securities to be offered to employees in employee..
8/02/202308:34EDGAR2Form S-3 - Registration statement under Securities Act of..
8/02/202307:11GLOBEAmarin Reports Second Quarter 2023 Financial Results
8/02/202307:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/02/202307:01EDGAR2Form 8-K - Current report
7/31/202308:00GLOBEAmarin and Lotus Pharmaceuticals Announce Exclusive..
7/28/202318:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
7/26/202308:00GLOBELatest Research Evaluating Clinical Benefits of..
7/25/202316:05GLOBEAmarin Receives Positive Recommendation from Spanish Drug..
7/24/202321:24EDGAR2Form 8-K - Current report
7/21/202321:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202321:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202321:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202321:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202321:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202321:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202321:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202321:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202317:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/21/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/20/202308:31EDGAR2Form 8-K - Current report
7/20/202308:00GLOBEAmarin Board of Directors Announces Executive Compensation..
7/18/202316:25EDGAR2Form 8-K - Current report
7/18/202316:16GLOBEAmarin Appoints Patrick Holt as President and Chief..
7/18/202316:15GLOBEAmarin Implements Organizational Restructuring to Strengthen..
7/05/202316:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
6/21/202309:00GLOBEAmarin Announces Vascepa® (Icosapent Ethyl) Approved to..
6/01/202316:30GLOBEAmarin to Present at Two Upcoming Investor Conferences

Your Recent History

NASDAQ
AMRN
Amarin
Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com